Clinical trials: Metastatic Cancer, completed
Endometrial Stromal Sarcoma, Adenosarcoma of Uterus
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
This phase 2 clinical trial aims to evaluate the efficacy of Fulvestrant, an ER-antagonist, in women with estrogen receptor positive (ER+) low-grade gynecological cancers.
- Conditions
- Endometrial Stromal Sarcoma, Adenosarcoma of Uterus, Leiomyosarcoma Uterus, Endometrial Cancer
- Trial name
- FUCHSia (NCT03926936)
- Testing
- Fulvestrant
- Where
- 14 sites in Belgium, Netherlands
- Volunteers
- 17 people
- Sponsor
- Frederic Amant
Cancer
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of apatinib with nivolumab treatment in participants with unresectable or metastatic cancer.
- Trial name
- NCT03396211
- Testing
- Apatinib, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Elevar Therapeutics
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00053209
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 121 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Advanced Solid Tumor
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
This is a first-in-human (FIH) phase 1 open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL501 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary anti-tumor…
- Trial name
- NCT05101109
- Testing
- ABL501
- Where
- 4 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- ABL Bio, Inc.
Breast Cancer
FDHT PET and Bicalutamide in Metastatic Breast Cancer
Rationale: The purpose is to evaluate whether non-invasive in vivo imaging of androgen receptor (AR) presence in metastatic breast cancer patients by means of 18F-fluoro-dihydrotestosterone positron emission tomography (FDHT-PET)…
- Trial name
- NCT02697032
- Testing
- Bicalutamide, FDHT PET
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- University Medical Center Groningen
Kidney Cancer
Bortezomib in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276614
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of capecitabine when given together with oxaliplatin, leucovorin calcium, and fluorouracil in treating patients with advanced cancer that is metastatic or cannot be…
- Trial name
- NCT00043121
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Cancer
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592).
- Trial name
- CUPID (NCT04726033)
- Testing
- 64Cu-DOTA-TLX592
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Lung Cancer, Lung Metastases
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib in combination with steroids, has on the lungs. Furthermore, such treatments' side effects will be studied together with quality of life.
- Trial name
- NCT02496585
- Testing
- Nintedanib, Prednisone
- Where
- 12 sites in United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Colorectal
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
Subjects will be entered into cohorts of 3 for the dose escalation phase so that the maximum tolerated dose can be determined. 18 additional patients will be recruited once the maximum tolerated dose (MTD) is determined for…
- Trial name
- NCT00540943
- Testing
- Pazopanib, Cetuximab, Irinotecan
- Where
- 2 sites in France
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014144
- Testing
- gefitinib
- Where
- 95 sites in United States
- Volunteers
- 31 people
- Sponsor
- SWOG Cancer Research Network
Renal Cell Carcinoma, Kidney Cancer
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma.
- Trial name
- NCT00496587
- Testing
- Capecitabine, Gemcitabine, Bevacizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms, Lung
The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine
Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs.
- Trial name
- NCT02115958
- Testing
- cancer stem cell vaccine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Stomach Neoplasms
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antitumor response of ramucirumab in combination with platinum/fluoropyrimidine regimens in Japanese participants with advanced…
- Trial name
- NCT02359058
- Testing
- Ramucirumab, Capecitabine, Cisplatin
- Where
- 4 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
NSCLC (Non-small-cell Lung Cancer)
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer (NSCLC)
- Trial name
- NCT05118334
- Testing
- Sintilimab, IBI310
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Pancreatic Tumours, Midgut Neuroendocrine Tumours
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine…
- Trial name
- CLARINET FORTE (NCT02651987)
- Testing
- Lanreotide autogel 120 mg
- Where
- 32 sites in Belgium, Denmark and 8 more
- Volunteers
- 99 people
- Sponsor
- Ipsen
HER2-positive Breast Cancer
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT04756921
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Biyun Wang, MD
Colorectal Neoplasms
A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer.
- Trial name
- NCT00730158
- Testing
- KD018, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Edward Chu, MD
Uterine Cervical Cancer
A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer
The following is an open label, non comparative, pilot study of palliative treatment as a second, third line or more of treatment in patients with recurrent, persistent or Metastatic Cervical Cancer; it has a limited sample of 15…
- Trial name
- NCT02095119
- Testing
- Nimotuzumab, Cisplatin, Gemcitabine
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- National Institute of Cancerología
Leukemia
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of bone marrow and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899171
- Testing
- DNA analysis, DNA methylation analysis, RNA analysis
- Volunteers
- 251 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.